Overview
Metastatic malignant neoplasms involving the cardia of the stomach represent a challenging clinical scenario, often diagnosed at advanced stages. These cases typically present with significant morbidity and are associated with poor prognoses, underscoring the need for comprehensive multidisciplinary management strategies. The epidemiology highlights a male predominance and frequent presentation at stage IV, emphasizing the urgency for early detection and intervention. Clinical management focuses on balancing palliative care with aggressive therapeutic approaches, aiming to improve both survival and quality of life. This guideline synthesizes current evidence to guide clinicians in the diagnosis, management, and supportive care of patients with metastatic gastric cancer involving the cardia.
Epidemiology
The epidemiology of metastatic malignant neoplasms in the cardia of the stomach reveals several critical patterns. A study involving 145 patients indicated a male predominance, with over half (64.83%) being male, suggesting potential gender-specific risk factors or diagnostic biases [PMID:31066594]. Notably, the majority (79.56%) of these patients were diagnosed at stage IV, highlighting the advanced nature of the disease at initial presentation. This advanced stage at diagnosis often limits the efficacy of curative treatments, necessitating a focus on palliative care strategies from the outset. Understanding these demographic and staging trends is crucial for tailoring early interventions and patient counseling regarding prognosis and treatment expectations.
Diagnosis
Diagnosing metastatic malignant neoplasms in the cardia of the stomach typically involves a combination of clinical symptoms, imaging studies, and histopathological confirmation. Common presenting symptoms include progressive dysphagia, weight loss, abdominal pain, and gastrointestinal bleeding, reflecting the advanced nature of the disease [PMID:31066594]. Imaging modalities such as CT scans and endoscopic ultrasonography (EUS) play pivotal roles in staging the extent of metastasis, particularly to regional lymph nodes and distant organs like the liver and peritoneum. Histopathological examination through endoscopic biopsies or surgical specimens confirms the diagnosis and identifies the specific histological subtype, which is essential for guiding targeted therapy decisions. Despite advancements, early detection remains challenging, underscoring the importance of vigilant clinical surveillance and prompt diagnostic workup.
Clinical Presentation
Patients with metastatic malignant neoplasms in the cardia of the stomach often present with a constellation of symptoms indicative of advanced disease. Dysphagia, frequently reported by 66% of patients, is a hallmark symptom, reflecting tumor obstruction or infiltration [PMID:31066594]. Additionally, significant weight loss, often exceeding 10% of body weight, is common and underscores the systemic impact of the malignancy. Abdominal pain, both epigastric and diffuse, is another frequent complaint, often exacerbated by tumor growth and potential peritoneal involvement. Gastrointestinal bleeding, though less common, can occur due to ulceration or erosion of tumor masses into vascular structures. These symptoms not only complicate daily functioning but also signal the need for urgent clinical evaluation and intervention.
Management
First-Line Therapy
The management of metastatic gastric cancer typically begins with systemic therapy, given the poor prognosis associated with advanced disease. Approximately 66% of patients receive doublet chemotherapy regimens, with combinations like 5-fluorouracil (5-FU) and cisplatin being the most prevalent, despite their limited efficacy [PMID:31066594]. Other common combinations include 5-FU with leucovorin, reflecting a reliance on established protocols despite only about 10% of patients achieving a response to first-line treatments. The modest response rates highlight the necessity for ongoing research into novel therapeutic targets and combinations to improve outcomes.
Second-Line and Beyond
For patients who progress on first-line therapy, second-line treatments are initiated in about 41.38% of cases, often due to disease progression or intolerance to initial regimens [PMID:31066594]. Commonly used agents in this setting include paclitaxel, capecitabine, irinotecan, and cisplatin, each offering varying degrees of efficacy and tolerability profiles. These treatments aim to extend survival and alleviate symptoms, though their impact remains limited compared to first-line therapies. The decision to proceed with second-line therapy should be individualized, considering patient performance status, comorbidities, and quality of life considerations.
Palliative Invasive Interventions
The role of palliative invasive interventions (PIG) in managing metastatic gastric cancer remains nuanced. A retrospective study involving patients with metastatic gastric cancer found no significant difference in overall survival between those who underwent PIG (such as surgical debulking, radiofrequency ablation, or cryoablation) and those who did not, with median survival times of 13.0 months in both groups [PMID:35112313]. However, these interventions can offer symptomatic relief and potentially improve quality of life, particularly in carefully selected patients. Cryoablation, for instance, has shown promising results in managing liver metastases, with a median overall survival of 16.0 months and improved quality of life, albeit with mild complications [PMID:29679550]. Thus, while survival benefits may be modest, the potential for enhanced quality of life supports considering PIG in appropriate clinical scenarios.
Multimodal Approaches
In select cases, multimodal approaches combining surgery, hyperthermic intraperitoneal chemotherapy (HIPEC), and other interventions can yield prolonged survival despite recurrence. A case report detailing a patient with advanced gastric cancer (pT3N2M1 with peritoneal and ovarian metastases) who survived 32 months post-diagnosis following radical surgery, HIPEC, and early postoperative intraperitoneal chemotherapy (EPIC) exemplifies the potential benefits of such aggressive multimodal strategies [PMID:24329514]. This approach underscores the importance of individualized treatment plans, particularly in patients with limited metastatic burden and favorable performance status. However, these cases are exceptions, and the applicability of such aggressive strategies must be carefully evaluated on a case-by-case basis.
Supportive Care and Palliative Measures
Supportive care and palliative measures are integral to managing symptoms and improving quality of life for patients with metastatic gastric cancer. Facilitated conversations about end-of-life preferences have shown that approximately 20% of patients revise their preferences, often opting for less intensive care [PMID:29298109]. This highlights the dynamic nature of patient wishes and the importance of ongoing dialogue regarding goals of care. Additionally, formal recognition and certification in palliative medicine can significantly enhance the quality of care provided, ensuring that patients and their families receive comprehensive support throughout the disease trajectory [PMID:15130199]. Regular reassessment and adaptation of care plans based on patient feedback and clinical progression are essential.
Complications
Patients undergoing palliative interventions, such as cryoablation, face specific complications that must be carefully monitored. While cryoablation has demonstrated promising outcomes in terms of survival and quality of life, the reported complications are generally mild, with no severe adverse events noted in a study involving 19 patients [PMID:29679550]. Common side effects include local pain, transient fever, and minor bleeding, which are manageable with appropriate supportive care. However, clinicians must remain vigilant for potential long-term effects and ensure that any intervention aligns with the patient's overall health status and quality of life goals.
Prognosis & Follow-Up
The prognosis for patients with metastatic gastric cancer remains challenging, with an overall median survival of 12.9 months (95% CI, 10.9-14.9) across various studies [PMID:35112313]. During follow-up, disease progression is observed in approximately 52% of patients, while stable disease is achieved in about 20%, indicating a significant clinical challenge [PMID:31066594]. For those treated with cryoablation, survival outcomes show encouraging figures, with 1-, 2-, and 3-year overall survival rates of 78.9%, 43.4%, and 21.7%, respectively [PMID:29679550]. Local tumor progression-free survival post-cryoablation is notable, with 59.2% and 23.2% rates at 6 and 12 months, respectively, suggesting that while systemic progression remains a concern, local control can be effectively managed in some cases. Continuous monitoring and adaptive management strategies are crucial to address both disease progression and patient-specific needs throughout the course of the illness.
Key Recommendations
References
1 Ekinci F, Erdoğan AP. The Effect of Palliative Invasive Interventions on Overall Survival in the Last 3 Months of Life in Metastatic Gastric Cancer. Journal of gastrointestinal cancer 2022. link 2 Novick D, Leonardi F, Lee Kay Pen D, Montoya-Restrepo ME, Avendaño C, Siddi S et al.. Retrospective analysis of patients with advanced or metastatic gastric cancer in Colombia. Journal of medical economics 2019. link 3 Chang X, Wang Y, Yu HP, Zhang WH, Yang XL, Guo Z. CT-guided percutaneous cryoablation for palliative therapy of gastric cancer liver metastases. Cryobiology 2018. link 4 Hopping-Winn J, Mullin J, March L, Caughey M, Stern M, Jarvie J. The Progression of End-of-Life Wishes and Concordance with End-of-Life Care. Journal of palliative medicine 2018. link 5 Hoskovec D, Varga J, Antos F, Kaspar M, Vitek P, Benkova K et al.. Palliative treatment of the advanced gastric cancer by means of surgery and HIPEC. Bratislavske lekarske listy 2013. link 6 von Gunten CF, Lupu D. Development of a medical subspecialty in palliative medicine: progress report. Journal of palliative medicine 2004. link
6 papers cited of 7 indexed.